Point72 Asia Singapore Pte. Ltd. Sells 750 Shares of Afya Limited (NASDAQ:AFYA)

Point72 Asia Singapore Pte. Ltd. trimmed its position in Afya Limited (NASDAQ:AFYAFree Report) by 21.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,752 shares of the company’s stock after selling 750 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Afya were worth $49,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Dodge & Cox raised its position in Afya by 7.0% during the 4th quarter. Dodge & Cox now owns 29,183 shares of the company’s stock worth $640,000 after buying an additional 1,900 shares during the last quarter. Lifestyle Asset Management Inc. grew its holdings in Afya by 26.9% in the second quarter. Lifestyle Asset Management Inc. now owns 14,784 shares of the company’s stock valued at $261,000 after purchasing an additional 3,133 shares during the period. Campbell & CO Investment Adviser LLC raised its position in Afya by 56.6% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 28,608 shares of the company’s stock worth $627,000 after acquiring an additional 10,337 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Afya by 136.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 35,254 shares of the company’s stock worth $622,000 after buying an additional 20,370 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Afya by 19.7% in the 2nd quarter. Renaissance Technologies LLC now owns 266,500 shares of the company’s stock valued at $4,704,000 after purchasing an additional 43,800 shares during the last quarter. 88.02% of the stock is currently owned by hedge funds and other institutional investors.

Afya Stock Performance

NASDAQ:AFYA opened at $17.07 on Tuesday. The firm has a 50 day simple moving average of $17.21 and a 200-day simple moving average of $17.59. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.47 and a quick ratio of 1.47. Afya Limited has a 1-year low of $14.57 and a 1-year high of $22.48. The firm has a market cap of $1.60 billion, a PE ratio of 15.95, a P/E/G ratio of 0.45 and a beta of 0.92.

Afya (NASDAQ:AFYAGet Free Report) last announced its earnings results on Thursday, August 15th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.06. The business had revenue of $155.40 million during the quarter, compared to the consensus estimate of $151.83 million. Afya had a net margin of 18.12% and a return on equity of 18.82%. On average, equities analysts expect that Afya Limited will post 1.52 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AFYA. UBS Group assumed coverage on shares of Afya in a report on Friday, August 30th. They issued a “neutral” rating and a $19.50 price objective for the company. Morgan Stanley lowered their target price on Afya from $21.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, June 21st.

View Our Latest Research Report on AFYA

Afya Profile

(Free Report)

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

Featured Stories

Institutional Ownership by Quarter for Afya (NASDAQ:AFYA)

Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.